114 related articles for article (PubMed ID: 15864822)
1. Therapy for colorectal cancer.
Jankilevich G
N Engl J Med; 2005 Apr; 352(17):1820-2; author reply 1820-2. PubMed ID: 15864822
[No Abstract] [Full Text] [Related]
2. Predictive value of microsatellite instability for benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
Jover R; Castells A; Llor X; Andreu M
Gut; 2006 Dec; 55(12):1819-20. PubMed ID: 17124161
[No Abstract] [Full Text] [Related]
3. Predictive value of microsatellite instability for benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
Iacopetta B; Watanabe T
Gut; 2006 Nov; 55(11):1671-2. PubMed ID: 17047121
[No Abstract] [Full Text] [Related]
4. Prognostic significance of interaction between somatic APC mutations and 5-fluorouracil adjuvant chemotherapy in Taiwanese colorectal cancer subjects.
Chen SP; Wu CC; Lin SZ; Kang JC; Su CC; Chen YL; Lin PC; Chiu SC; Pang CY; Harn HJ
Am J Clin Oncol; 2009 Apr; 32(2):122-6. PubMed ID: 19307944
[TBL] [Abstract][Full Text] [Related]
5. [Anaphylactoid shock due to folinic acid during treatment of metastatic colorectal cancer].
Benoit R; Grobost O; Chalmet P
Gastroenterol Clin Biol; 2000 Dec; 24(12):1241-2. PubMed ID: 11173744
[No Abstract] [Full Text] [Related]
6. Microsatellite instability in colon cancer.
Allegra CJ; Kim G; Kirsch IR
N Engl J Med; 2003 Oct; 349(18):1774-6; author reply 1774-6. PubMed ID: 14585950
[No Abstract] [Full Text] [Related]
7. Lack of benefit of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer with microsatellite instability.
Johnson L; Chu E
Clin Colorectal Cancer; 2002 Nov; 2(3):146-8. PubMed ID: 12482330
[No Abstract] [Full Text] [Related]
8. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemotherapy of colorectal cancer.
Cunningham D; Starling N
Lancet; 2007 Dec; 370(9604):1980-1. PubMed ID: 18083386
[No Abstract] [Full Text] [Related]
10. Cancers of the large bowel and hepatobiliary tract.
Vaughn DJ; Treat J
Cancer Chemother Biol Response Modif; 1996; 16():495-510. PubMed ID: 8639398
[No Abstract] [Full Text] [Related]
11. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status.
Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Balaguer F; Sempere L; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Pons E; Payá A; Alenda C;
Eur J Cancer; 2009 Feb; 45(3):365-73. PubMed ID: 18722765
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience.
Wilson KS; Fitzgerald CA; Barnett JB; Gill S; Khoo KE
Cancer Invest; 2007 Dec; 25(8):711-4. PubMed ID: 18058467
[TBL] [Abstract][Full Text] [Related]
13. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Piñol V; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Payá A; Alenda C;
Gut; 2006 Jun; 55(6):848-55. PubMed ID: 16299036
[TBL] [Abstract][Full Text] [Related]
14. The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients.
Zhou ZW; Wang GQ; Wan de S; Lu ZH; Chen YB; Li S; Chen G; Pan ZZ
Chemotherapy; 2007; 53(2):127-31. PubMed ID: 17308379
[TBL] [Abstract][Full Text] [Related]
15. Neutrophil and monocyte phagocytic functions in patients with colorectal adenocarcinoma during fluorouracil therapy.
Lukac J; Kusić Z; Kovacević D; Soldić Z; Troskot B
Anticancer Res; 1995; 15(6B):2805-9. PubMed ID: 8669869
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
Yamada H; Iinuma H; Watanabe T
Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy.
Sobrero A; Guglielmi A; Grossi F; Puglisi F; Aschele C
Semin Oncol; 2000 Oct; 27(5 Suppl 10):72-7. PubMed ID: 11049035
[No Abstract] [Full Text] [Related]
18. SMAD4 levels and response to 5-fluorouracil in colorectal cancer.
Alhopuro P; Alazzouzi H; Sammalkorpi H; Dávalos V; Salovaara R; Hemminki A; Järvinen H; Mecklin JP; Schwartz S; Aaltonen LA; Arango D
Clin Cancer Res; 2005 Sep; 11(17):6311-6. PubMed ID: 16144935
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant therapy of colorectal cancer.
Midgley RS; Kerr DJ
Hosp Pract (1995); 2000 May; 35(5):55-62; quiz 122. PubMed ID: 10844908
[No Abstract] [Full Text] [Related]
20. Adjuvant chemotherapy for rectal cancer.
Bujko K; Bujko M
Lancet; 2008 May; 371(9623):1502-3; author reply 1503. PubMed ID: 18456096
[No Abstract] [Full Text] [Related]
[Next] [New Search]
